Bristol-Myers Squibb stock holds near $67 after Q2 miss
Published on 08/29/2026 at 11:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol-Myers Squibb (US1078421011) stock traded at $67.14 on August 28, 2026, with a one-day move of -0.6% and a 52-week range of $42.52 to $68.64. The company also posted Q2 2026 revenue of $11.74 billion and EPS of $1.62, while listed consensus revenue for the quarter stood at $12.97 billion.
Quarterly gap still matters
The quarter left a clear comparison point: revenue fell $1.23 billion short of the $12.97 billion benchmark, even as EPS improved by $0.02 from $1.60 to $1.62. That mix explains why the shares can sit close to the top of the 52-week range without breaking decisively above it.
Analyst data in the same market snapshot put the average target at $66.21, which leaves the stock slightly above that level at $67.14. The gap is modest, but it shows the market is already pricing in much of the recent earnings picture.
Valuation and peer angle
The same snapshot listed a market cap of $136.004 billion and a trailing P/E of 14.67. For a large pharmaceutical name, that combination points to a mature earnings profile rather than a high-growth multiple.
Compared with Merck, AbbVie, and Amgen, Bristol-Myers Squibb sits in the same defensive healthcare lane but at a smaller market value than those larger peers. That relative scale matters because it leaves less room for surprise on the top line and keeps pipeline execution in sharp focus.
Oncology remains central
The company's oncology franchise still anchors the investment case, with products such as Opdivo and Breyanzi carrying much of the portfolio weight. The July 15, 2026 comparison snapshot tied that broader franchise strength to the $11.74 billion quarterly revenue print and the $1.62 EPS result.
For investors, the key question is whether future quarters can close the gap between reported sales and the $12.97 billion consensus level while keeping EPS on a stable path. The current setup suggests a stock that is being judged on execution more than on multiple expansion.
Trading around the high end
At $67.14, the shares were trading less than $1.50 below the $68.64 52-week high on August 28, 2026. That leaves Bristol-Myers Squibb in a tight band where earnings delivery and pipeline updates can matter more than broad market sentiment.
The stock closed the session in the mid-$60s on the New York Stock Exchange, with after-hours trading adding only a small move to $66.60. The price action keeps the focus on whether the next update can justify a push beyond the recent range.
More on Bristol-Myers Squibb stock
Bristol-Myers Squibb sells cancer, immunology, cardiovascular, and neuroscience medicines worldwide, with Opdivo, Orencia, Yervoy, Breyanzi, and Camzyos among its best-known products.
Fact box
Company: Bristol-Myers Squibb Inc.
ISIN: US1078421011
Ticker: BMY
Exchange: New York Stock Exchange
Price (as of August 28, 2026): $67.14 USD
Market cap: $136.004 billion (as of August 28, 2026)
Sector / Industry: Healthcare / Drug Manufacturers - General
Index membership: S&P 500
Next earnings date: October 29, 2026
More on Bristol-Myers Squibb stock
The stock's recent range of $42.52 to $68.64 gives traders a clear frame, and the current level remains close to the upper end of that band.
